Danaher Schedules Third Quarter 2024 Earnings Conference Call
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
Is It Too Late To Consider Buying Danaher Corporation (NYSE:DHR)?
Deutsche Bank Raises Price Target on Danaher to $285 From $270
Danaher To Go Ex-Dividend On September 27th, 2024 With 0.27 USD Dividend Per Share
September 10th (Eastern Time) - $Danaher(DHR.US)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 27th, 2024 will receive 0.27 USD dividend per share on October 25
Danaher Keeps Quarterly Dividend at $0.27 a Share, Payable Oct. 25 to Shareholders of Record Sept. 27
Press Release: Danaher Announces Quarterly Dividend
Unpacking the Latest Options Trading Trends in Danaher
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
RBC Capital Reiterates Outperform on Danaher, Maintains $300 Price Target
A Quick Look at Today's Ratings for Danaher(DHR.US), With a Forecast Between $275 to $310
On Sep 06, major Wall Street analysts update their ratings for $Danaher(DHR.US)$, with price targets ranging from $275 to $310.BofA Securities analyst Michael Ryskin maintains with a hold rating,
Jefferies Sticks to Its Buy Rating for Danaher (DHR)
Smart Money Is Betting Big In DHR Options
Integrated DNA Technologies Bolsters Comprehensive Genomic Profiling Solutions With Launch of New Archer HRD Technology for Cancer Research
Wells Fargo Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $280
Wells Fargo analyst Brandon Couillard maintains $Danaher(DHR.US)$ with a hold rating, and maintains the target price at $280.According to TipRanks data, the analyst has a success rate of 63.2% and a
Danaher Still Expects Adj Core Rev Down Low-Single Digits Yr-over-Yr for 3Q, FY24 >DHR
Leerink Partners Maintains Danaher(DHR.US) With Buy Rating, Maintains Target Price $280
Leerink Partners analyst Puneet Souda maintains $Danaher(DHR.US)$ with a buy rating, and maintains the target price at $280.According to TipRanks data, the analyst has a success rate of 34.9% and a
Danaher Confirms Third Quarter and Full Year 2024 Guidance
Is Danaher Corporation (DHR) the Best Cancer Stock to Buy Now?
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?